Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pegylated protamine
- Development stage
- Unknown
- Modality
- Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Pegylated protamine is likely a modified version of protamine, which is a medication used to reverse the anticoagulant effects of heparin. Protamine is a strongly alkaline polycationic protein, often derived from salmon sperm or produced through recombinant technology. PEGylation, the process of attaching polyethylene glycol (PEG) to molecules, can enhance the stability, solubility, and pharmacokinetic profile of drugs. In the context of nanopharmaceuticals and drug delivery systems, pegylated protamine could potentially be used to improve the delivery of drugs, leveraging protamine's cell-penetrating properties.
Beyond the preview
Go deeper on Pegylated protamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pegylated protamine.